Home » Stocks » XERS

Xeris Pharmaceuticals, Inc. (XERS)

Stock Price: $5.34 USD 0.06 (1.14%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $5.32 -0.02 (-0.38%) Jan 22, 7:59 PM
Market Cap 261.53M
Revenue (ttm) 15.09M
Net Income (ttm) -102.37M
Shares Out 46.15M
EPS (ttm) -2.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $5.34
Previous Close $5.28
Change ($) 0.06
Change (%) 1.14%
Day's Open 5.20
Day's Range 5.19 - 5.44
Day's Volume 1,035,102
52-Week Range 1.49 - 6.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 2 weeks ago

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ...

Business Wire - 3 weeks ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Business Wire - 1 month ago

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Business Wire - 1 month ago

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...

Business Wire - 1 month ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Seeking Alpha - 2 months ago

Last year, I was neutral about the Xeris Pharmaceuticals story; but a lot of positives have happened this year. There's a marketed product, a steadily rising revenue stream, a platform with po...

Seeking Alpha - 2 months ago

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 35.19% and 111.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead fo...

Benzinga - 2 months ago

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) moved higher by 4.6% in pre-market trading after the company reported Q3 results.

Business Wire - 2 months ago

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...

Business Wire - 2 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...

Zacks Investment Research - 2 months ago

Xeris Pharmaceuticals (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Business Wire - 4 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Seeking Alpha - 4 months ago

Xeris has rallied substantially off its recent lows as Gvoke sales numbers have been promising.

Business Wire - 5 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.

Zacks Investment Research - 5 months ago

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares more than 5% on the day, amid huge volumes.

Seeking Alpha - 5 months ago

Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 11.27% and -11.18%, respectively, for the quarter ended June 2020.

Benzinga - 5 months ago

Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 3% in pre-market trading after the company reported Q2 results.

Business Wire - 5 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...

Business Wire - 5 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize read...

Business Wire - 5 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Zacks Investment Research - 5 months ago

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Business Wire - 6 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Business Wire - 6 months ago

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and co...

Zacks Investment Research - 6 months ago

Xeris Pharmaceuticals (XERS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Business Wire - 6 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Business Wire - 7 months ago

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use inj...

Seeking Alpha - 8 months ago

Xeris Pharmaceuticals' (XERS) CEO Paul Edick on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Xeris Pharmaceuticals.

Seeking Alpha - 10 months ago

Xeris Pharmaceuticals, Inc.'s (XERS) CEO Paul Edick on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 0.81% and 144.30%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 10 months ago

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 11 months ago

CHICAGO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...

GlobeNewsWire - 11 months ago

CHICAGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...

Benzinga - 1 year ago

Xeris Pharmaceuticals Inc (NASDAQ: XERS) shares are advancing on above-average volume Tuesday following a positive data readout from the company.

24/7 Wall Street - 1 year ago

Xeris Pharmaceuticals, Inc. shares pushed higher on Tuesday after the firm announced positive topline results from its mid-stage study in adults with Type 1 diabetes mellitus (T1D).

Market Watch - 1 year ago

Xeris Pharmaceuticals Inc. shares rallied in the extended session Monday after the drug maker said its diabetes treatment showed positive results in a mid-stage clinical study.

GlobeNewsWire - 1 year ago

CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...

GlobeNewsWire - 1 year ago

CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commerciali...

GlobeNewsWire - 1 year ago

MAA submitted to EMA of liquid stable glucagon for severe hypoglycemia GVOKE ™ PFS launch underway GVOKE HypoPen ™ expected to launch July 2020 CHI program shifts to Expanded Acce...

Zacks Investment Research - 1 year ago

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of 3.17% and 61.50%, respectively, for the quarter ended September 2019.

Zacks Investment Research - 1 year ago

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 1 year ago

CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercial...

24/7 Wall Street - 1 year ago

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) shares were halted briefly on Tuesday after the firm announced that it has received regulatory approval from the U.S.

Seeking Alpha - 1 year ago

Xeris Pharma’s Gvoke is a stable and ready to use glucagon self-injector therapy.

About XERS

Xeris Pharmaceuticals, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
CEO
paul Edick
Employees
172
Stock Exchange
NASDAQ
Ticker Symbol
XERS
Full Company Profile

Financial Performance

In 2019, XERS's revenue was $2.72 million, an increase of 12.34% compared to the previous year's $2.42 million. Losses were -$125.58 million, 109.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 105.99% from the latest price.

Price Target
$11.00
(105.99% upside)
Analyst Consensus: Strong Buy